Ultragenyx rises after FDA nod for rare disorder drug
RARE•Abeona licensing deal and share moves
-
Abeona Therapeutics
ABEO.Oout-licensed Fayuvi to Ultragenyx in 2022, granting the company global development and commercialization rights for the therapy. -
ABEOshares were up 3.5% premarket. -
ABEOis eligible to receive certain commercial milestone payments and royalties tied to future product sales. -
As of the last close,
RAREshares were down about 37% year to date.
Ultragenyx shares rise after FDA approval of gene therapy
-
Shares of drugmaker Ultragenyx Pharmaceutical
RARE.Orose 1% to $14.65 premarket, after closing up 12.58% on Thursday. -
The U.S. Food and Drug Administration late on Thursday approved Ultragenyx's gene therapy, Fayuvi, as the first treatment for children with Sanfilippo syndrome Type A.
-
Sanfilippo syndrome Type A is an inherited condition that progressively damages the brain and nervous system.
